当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Dorra Ben Sellem, Waisse Waissi, Mojdeh Dormishian, Caroline Bund, Jean-Louis Dietemann, Marie-Pierrette Chenard, Georges Noël and Izzie- Jacques Namer*
Aim: The purpose of this study was to investigate prospectively the predictive value of positron emission tomography with proton magnetic resonance spectroscopic imaging (MRSI) and 18F-fluorodeoxyglucose (FDG-PET) performed the 1st month after surgery and before radio- chemotherapy in 43 patients with glioblastoma (GBM).
Patients and methods: Metabolite concentrations were quantified using LCModel. Overall survival (OS) and progression free survival (PFS) were calculated including all 43 patients using Kaplan-Meier curves, and the Cox proportional hazard model was used to calculate the predictor of survival.
Results: At the end of the follow-up period, all patients died within a period of 1–70.2 months. In 32 patients (74.4%), increased FDG-uptake was seen around the resection cavity and abnormal metabolic profiles on MRSI, indicative of residual disease, were present in all patients. There was no significant difference between the median OS in patients with hypometabolic FDG lesions compared to patients with hypermetabolic FDG lesions. On univariate analysis, normalized choline-containing compounds/creatine (nCho/Cr) and normalized lactate/creatine (nLac/Cr) were significantly predictive of OS and nLac/Cr and normalized N-Acetylaspartylglutamate and NAcetylaspartate/ creatine (NAA/Cr) were significantly predictive of PFS.
Conclusions: nCho/Cr and nLac/Cr ratio after surgery and before radio-chemotherapy were independent metabolic predictive factors of OS times in newly diagnosed patients with GBM.